Plans are also underway to begin three additional Phase Ib expansion studies focusing on different combinations and patient ...

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program ...

Metastatic castration-resistant prostate cancer (mCRPC) is diagnosed by blood tests, imaging scans, and biopsies. Find out ...

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment ...

Having detectable ctDNA before treatment is associated with worse outcomes among patients with mCRPC, regardless of the treatment they receive.

AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared ...

The median overall survival was 19.6 months with pembrolizumab plus docetaxel and 19.0 months with docetaxel alone. The combination of pembrolizumab and docetaxel does not improve outcomes over ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] ...

AstraZeneca has announced the discontinuation of the CAPItello-280 Phase III trial evaluating the efficacy and safety of ...

The phase 3 trial enrolled 1033 patients who had not received prior chemotherapy for mCRPC and had evidence of disease progression despite androgen deprivation therapy.